Pancreatic cancer is a challenging disease to treat, and the prognosis for patients is often poor. However, recent developments in technology and treatment have shown promise in improving patient outcomes.
Innovations in Pancreatic Cancer Treatment
Clinical Trials
- Patients with pancreatic cancer are HIGHLY encouraged to participate in clinical trials.
- Patients at risk of developing pancreatic cancer are encouraged to participate in studies like those being conducted by the PRECEDE Consortium to find the cancer at its earliest, most treatable stage.
- Participating in clinical trials has been shown to improve outcomes for pancreatic cancer patients.
- By participating in clinical trials, patients would be closely monitored and have access to the newest treatment and screening tests, which can help that patient potentially achieve a better outcome.
- Clinical trials can lead to improved options available for the future treatment of pancreatic cancer.
Minimally invasive surgery
- Pancreatic tumors can be removed through robotic and laparoscopic surgery, which has the advantages of shorter recovery times and better results.
- Laparoscopic Surgery – To remove the tumor using this method, several small abdominal incisions are made, and a laparoscope—a long, thin tube with a camera and surgical tools attached—is inserted. Compared to open surgery, laparoscopic surgery has a number of advantages, such as:
- Fewer scars and smaller incisions
- Reduced loss of blood
- Faster times of recovery
- Lower possibility of complications
- Robotic Surgery – It uses robotic arms to perform the surgery. This technique offers several advantages , including:
- Increased precision and control
- Improved visualization of the surgical site
- Reduced tremors and hand fatigue for the surgeon
- Laparoscopic Surgery – To remove the tumor using this method, several small abdominal incisions are made, and a laparoscope—a long, thin tube with a camera and surgical tools attached—is inserted. Compared to open surgery, laparoscopic surgery has a number of advantages, such as:
As of now, surgery offers the best chance of treating pancreatic cancer. But, most patients are diagnosed at later stages and are not eligible for surgery. Developing early detection tools and tests for pancreatic cancer are urgently needed.
Nanoparticle Technology
- The NoCanTher project has developed a new technology that combines the injection of nanoparticles into the cancer with the application of hyperthermia to locally advanced pancreatic tumors.
- The technology aims to improve the effectiveness of chemotherapy and reduce side effects.
Nanofluidic Drug-Eluting Seed
- Researchers from Houston Methodist have developed a nanofluidic drug-eluting seed (NDES) that can deliver immunotherapy directly into a pancreatic tumor.
- The implantable device delivers CD40 monoclonal antibodies at a sustained low-dose.
- Ongoing studies will determine the safety and efficacy of the NDES in treating pancreatic cancer.
- The researchers hope to make this technology available as a treatment option for patients within the next five years.
The development of new technologies and treatments provides hope for improving the outcomes of pancreatic cancer patients. Clinical trials and innovative approaches like nanoparticle technology and the nanofluidic drug-eluting seed offer promising options for the future.
These treatments are still being studied, and not all patients may be eligible for them. With your donation, we can change the world. Giving is not just about making a donation, it’s about making a difference.
TrovaNOW is raising funds for PRECEDE – an international, multi-institutional collaborative consortium of world-renowned experts in pancreatic cancer.
At TrovaNOW, our mission is to increase pancreatic cancer survival rates through research, early detection, and prevention strategies.
With your help and donations, our research and data sharing can change the outcomes for patients diagnosed with pancreatic cancer.
Visit www.precedefoundation.org to learn how you can get involved and donate today.
